Danabol 50 mg

Danabol 50 mg contains methandienone, which is not FDA-approved for human use in the United States and is classified as a Schedule III controlled substance. It was historically accepted by the FDA in 1970 as "Probably Effective" for post-menopausal osteoporosis and pituitary-deficient dwarfism, but was later withdrawn. In non-medical bodybuilding contexts, it is commonly referenced as a mass-building compound, though such use is illegal and falls outside approved indications.

No FDA-approved human dosing exists for methandienone in the United States. Historical medical dosing referenced 2–8 mg daily in divided doses. In non-medical bodybuilding contexts, methandienone is commonly referenced at 10–50 mg daily for 4–6 weeks. These figures are anecdotal and lack clinical validation. Methandienone is banned by WADA and is prohibited at all times in sport.

Methandienone suppresses endogenous testosterone production, and post-cycle therapy is commonly recommended in non-medical contexts. Agents such as Clomid or Tamoxifen are commonly referenced for this purpose. However, no clinical data supports specific PCT protocols for methandienone use, and recovery may be incomplete.

Methandienone binds to androgen receptors, increasing protein synthesis and nitrogen retention in muscle tissue. It also inhibits glucocorticoid receptors, reducing catabolism and promoting anabolic effects. In historical medical use, it was used for osteoporosis and dwarfism, but it is no longer approved for human use in the United States.

Methandienone has a duration of action of approximately 12–24 hours. In non-medical contexts, community reports suggest initial changes in weight and strength may be noticed within 1–2 weeks, with more pronounced effects by week 3–4. However, no controlled human trials have characterized the onset of effects for non-medical use.

There is no clinical evidence to establish methandienone as superior to other compounds for any indication. Methandienone is associated with significant hepatotoxicity, cardiovascular risks, and hormonal suppression. It is not FDA-approved for human use and is banned in sport. The appropriate choice depends on the circumstances, and non-medical use falls outside approved indications.

Danabol (methandienone) is an aromatizing oral steroid associated with significant water retention and mass gains, while Anavar (oxandrolone) is a non-aromatizing oral steroid with a milder profile. Oxandrolone is FDA-approved for specific medical indications in the United States; methandienone is not approved for any human use and is a Schedule III controlled substance.

Danabol (methandienone) is aromatizable and associated with greater water retention, while Turinabol (4-chlorodehydromethyltestosterone) is not aromatizable and produces leaner gains. Both are 17-alpha-alkylated oral steroids and carry hepatotoxicity risks. Neither is FDA-approved for human use in the United States.

A milligram amount cannot be classified as appropriate or excessive without considering the medical indication, individual response, and other factors. Historical medical dosing referenced 2–8 mg daily, so 50 mg is above historical clinical dosing. It is also important to distinguish a dose from a product's tablet strength. Danabol 50 mg indicates 50 mg of methandienone per tablet; that strength does not by itself specify how much should be taken.

Danabol 50 mg is labeled at 50 mg of methandienone per tablet. It is supplied as oral tablets in a 100-tablet package.

Yes. A published laboratory report dated August 23, 2024 measured Danabol 50 mg at 49.14 mg, equivalent to 98.28% of its 50 mg label claim. The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report.

In non-medical bodybuilding contexts, methandienone is sometimes stacked with injectable testosterone or other anabolic compounds. However, methandienone is not FDA-approved for human use, and no clinical data exists to support any combination with other compounds. Because methandienone is 17-alpha-alkylated, concurrent use with other oral 17-alpha-alkylated steroids increases hepatotoxicity risk.